Castillo GLA

Idioma: Español
Referencias bibliográficas: 41
Paginas: 3-13
Archivo PDF: 512.75 Kb.

RESUMEN

La mucormicosis es una infección producida por un hongo, del género Rhizomucor, patógeno que, bajo condiciones de inmunocompromiso como diabetes y SIDA, produce enfermedad. Existen varias formas de presentación clínica: rinocerebral, pulmonar, mucocutánea, gastrointestinal y diseminada. La presentación rinocerebral es frecuentemente fatal, con una morbimortalidad de 85-100% a pesar del uso de la anfotericina B, terapia hiperbárica y resección quirúrgica agresiva.

REFERENCIAS (EN ESTE ARTÍCULO)

1. l. Collins DM, Dillard TA. Grathwohl KW et al. Bronchial mucormycosis with progressive air trapping. Mayo Clinic Proceedings 1999; 74(7): 698-701.

2. Gregory JE, Golden A, Haymaker E. Mucormycosis of the central nervous system: report of three cases. Bull Johns Hopkins 1943; 73: 405-19.

3. Plaignaud M. Observation sur fungus de sinus maxillaire. J Chir 1791; 1: 111-16.

4. Arenas R. Micología médica. 1a. Ed. Ed. Interamericana; 1993, p. 241-53.

5. Platauf A. Mycosis mucorina. Virchow Arch 1885; 102: 543-64.

6. Baker RD. Mucormycosis: a new disease? JAMA 1957; 163: 805-8.

7. Harris JS. Mucormycosis: a report of a case. Pediatrics 1955; 16: 857-67.

8. Chick EW, Evans J, Baker RD. The inhibitory effect of amphotericin B on localized Rhizopus oryzae infection utilizing pneumoderma pouch of rat. Antibiot Chemother 1958; 8: 506-10.

9. Chick EW, Evans J, Baker RD. Treatment of mucormycosis in rabbits with amphotericin B. Antibiot Chemother 1958; 8: 394-7.

10. Glazer, Mendel, Nusair et al. The role of BAL in the diagnosis of pulmonary mucormycosis. Chest 1999 ; 117: 279-82.

11. Wall SJ, Lee KH, Alvarez JD. Quiz case 1. Archives of Otorryn- Head and Neck Surgery. 126: 236-239

12. Peterson KL, Wang M, Canalis RF, Abemayor E. Rhinocerebral mucormycosis: Evolution of the disease and treatment option. Laryngoscope 1997; 107: 855-62.

13. Rubin SA, Chaljub G, Winer-Muram HT, Flicker S. Pulmonary zymomucosis: a radiographic and clinical spectrum. J Thorac Imaging 192; 7: 85-90.

14. Adam RD. Hunter G. Mucormycosis: Emerging prominence of cutaneous infections. Clinc Infect Disease 1994; 125: 67-70.

15. Kellei MA, Wu Chin L. Weekly clinicophatological exercises: cases 22. 1999: a 68 year old woman with multiple myeloma, diabetes mellitus and an inflamed eye. New Eng J Med 1999; 241: 265-73.

16. deShazo, Richard D, O’Brien M, Chapin K, et al. A new classification and diagnostic criteria for invasive fungal sinusitis. Archives of Otolaringology-Head Neck Surgery; 123: 1181-8.

17. Heinz TP, Schell W. Soft-tissue fungal infections: Surgical management of 12 inmunocompromised patients. Plast Reconstr Surg 1996; 97: 1391.

18. Alder DE, Milhorat TH, John I. Treatment of rhinocerebral mucormycosis with intravenous, interstitial, and cerebrospinal fluid administration of amphotericin B: case report. Neurosurgery 1998; 42: 644-9.

19. Greenberg MR, Lippman SM, Grinnel VS, Colman MF. Computed tomographic findings in orbital mucor. West J Med 1985; 143: 102-3.

20. Anand VK, Alemar G, Griswold JA. Intracranial complications of mucormycosis: An experimental model and clinical review. Laryngoscope 1992; 102: 656-62.

21. Pagano L, Ricci P, Tonso A, Nasari A, et al. Mucormycosis in patient with heamatological malignancies: a retrospective clinical study of 37 cases. B J Haematol 1997; 99: 331-6.

22. Sanchez MR, Ponge WI. Zygomycosis ands HIV infection. J Am Acad Dermatol 1999; 30: 904-8.

23. Armstrong D. Treatment of opportunistic fungal infection. Clinic Infect Dis 1992; 16: 1-9.

24. Smith CM. Farmacología. 1a. Ed. Editorial Panamericana; 1996, p. 839-40.

25. Cuadrado LM, Guerrero A, Asenjo JLG, Martín F. Cerebral mucormycosis in two cases of acquired immunodeficiency syndrome. Arch Neurol 1998; 45: 109-11.

26. Masucci EF, Fabara JA, Saini N, Kurtzke JF. Cerebral mucormycosis in a heroin addict. Arch Neurol 1982; 39: 304-6.

27. Murphy RA, Miller WT Jr. Pulmonary mucormycosis. Semin Roentgenol 1996; 31: 83-7.

28. McAdams HP, Rosado de Christenson M, Strollo DC. Pulmonary mucormycosis: radiologic findings in 32 cases. AJR Am J Roentgenol 1997; 168: 1541-8.

29. Kucers A, Bennett N, Kemp RJ. The use of antibiotics: A comprehensive review with clinical emphasis. Philadelphia, J.B. Lippincott; 1987, p. 1449-50.

30. Robert HJ, Chesterman AT. Ampotericina B vía intravenosa. Indicaciones dús i criteris d´utilitzacióen les infeccions fúngiques sistemiques. Butlleti del medicament 1999; 1: 1231-6.

31. Cohen J. Antifungal chemotherapy. Lancet 1982; 2: 532-5.

32. Bell WE. Treatment of fungal infection of the central nervous system. Ann Neurol 1981; 9: 417-22.

33. Martindale CA. The complete drug reference XXXII. Londres: The Pharmaceutical Press; 1999, p. 372-5.

34. Schoffski P. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumoniaes or fever of unknown origin: randomized study. Brist J Med, 1998; 317: 379-84.

35. Walsh TJ. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl Med 1999; 340: 764-71.

36. Tollemar J, Rengden O. Lipid formulations of amphotericin B. Less toxicity but at what economic cost? Drugs Safety 1995; 13: 207-18.

37. Leenders AC. The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia 1996; 10: 1570-5.

38. Hamill R, Oney LA, Cranel LR. Successful therapy for rhinocerebral mucormycosis with associated bilateral brain abscesses. Arch Intern Med 1983; 141: 581-3.

39. Langmayr JJ, Schwarz A, Buchberger W, Hochleitner W. Local amphotericin for fungal brain abscess. Lancet 1993; 342: 123-7.

40. Jeffrey DM, Beeard ME, Ikram RB. Intranasal amphotericin B reduce the frequency of invasive aspergillosis in neutropenic patients. Am J Med 1991; 90: 685-92.

41. Bentur, Yedidia Shupak. Hyperbaric oxygen therapy for cutaneous/soft-tissue zygomycosis complicating diabetes mellitus. Plast Recons Surg 1998; 102: